<DOC>
	<DOCNO>NCT01106599</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I dose-escalation study ass safety , tolerability , pharmacokinetics GDC-0623 patient locally advance metastatic solid tumor . Patients enrol one two stage : dose-escalation stage ( Stage I ) follow expansion stage ( Stage II ) . Stage I evaluate safety , tolerability , pharmacokinetics increase dos GDC-0623 administer orally 21 day on/7-day dosing schedule .</brief_summary>
	<brief_title>A Study Evaluating Safety , Tolerability , Pharmacokinetics GDC-0623 Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically document , locally advanced metastatic solid tumor standard therapy either exist proven ineffective intolerable Evaluable disease disease measurable per RECIST Life expectancy &gt; = 12 week Adequate hematologic end organ function Agreement use effective form contraception duration study Consent provide archival tissue For cohort expansion stage ( Stage II ) : Patients cohort must four prior systemic therapy cancer must KRAS mutant CRC ( Stage II A B ) , pancreatic cancer ( Stage IIC , KRAS mutant NSCLC [ Stage IID ] ) History prior significant toxicity MEK pathway inhibitor require discontinuation treatment History parathyroid disorder history malignancyassociated hypercalcemia require therapy last 6 month History retinal vein occlusion ( RVO ) predispose factor RVO , include uncontrolled hypertension , uncontrolled diabetes , uncontrolled hyperlipidemia , coagulopathy Evidence visible retinal pathology consider risk factor retinal vein thrombosis History glaucoma Palliative radiotherapy , experimental therapy , anticancer therapy major surgical procedure within specify timeframe prior first dose study drug Current severe , uncontrolled systemic disease History clinically significant cardiac dysfunction History active gastrointestinal bleeding within 6 month prior screen Clinically significant history liver disease , current alcohol abuse , current know active infection HIV , hepatitis B C virus Active autoimmune disease Uncontrolled ascites Pregnancy , lactation , breastfeed Known brain metastasis untreated , symptomatic , require therapy control symptom For Exploratory PK Cohorts ( Stage IB Stage IC ) : Patients history ongoing gastroesophageal reflux disease peptic ulcer , gastric pathology history gastric surgery could affect absorption GDC0623 stomach , exclude cohort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>